Non-muscle-invasive bladder cancer: Intravesical treatments beyond Bacille Calmette-Guérin. Cancer 2017 Feb 01;123(3):390-400
Date
01/24/2017Pubmed ID
28112819DOI
10.1002/cncr.30392Scopus ID
2-s2.0-84996490487 (requires institutional sign-in at Scopus site) 53 CitationsAbstract
An unmet need exists for patients with high-risk non-muscle-invasive bladder cancer for whom bacille Calmette-Guérin (BCG) has failed and who seek further bladder-sparing approaches. This shortcoming poses difficult management dilemmas. This review explores previously investigated first-line intravesical therapies and discusses emerging second-line treatments for the heterogeneous group of patients for whom BCG has failed. The myriad of recently published and ongoing trials assessing novel salvage intravesical treatments offer promise to patients who both seek an effective cure and want to avoid radical surgery. However, these trials must carefully be contextualized by specific patient, tumor, and recurrence characteristics. As data continue to accumulate, there will potentially be a role for these agents as second-line or even first-line intravesical therapies. Cancer 2017;123:390-400. © 2016 American Cancer Society.
Author List
Packiam VT, Johnson SC, Steinberg GDAuthor
Scott C. Johnson MD Associate Professor in the Urology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Administration, IntravesicalBCG Vaccine
Disease Management
Female
Humans
Immunotherapy
Neoplasm Invasiveness
Neoplasm Recurrence, Local
Salvage Therapy
Treatment Failure
Urinary Bladder Neoplasms
